What happens when leaders
take psychedelics?

From the clinic to the boardroom

Clinical research has shown what psychedelics can do in controlled therapeutic settings. But that's not where most executives encounter them. They arrive at psilocybin retreats in Mexico, ketamine clinics, or ayahuasca ceremonies — carrying the pressures of investors, employees, and markets.

We want to understand attitudes toward psychedelics, motivations for use or non-use, and reported outcomes — across a diverse, global sample of leaders.

Rigorous science focused on real-life use

We're interested in the full picture — not just breakthrough moments. Not just increased empathy, but also the risk of grandiosity masquerading as insight. Not just expanded perspective, but also narrowed judgment wrapped in spiritual language.

Our team approaches this as neither advocates nor skeptics — only as researchers committed to understanding what's actually happening, in all its complexity.

Leaders at every point
on the spectrum

Must be 18+ and hold a leadership role — c-suite, founder, senior manager, or entrepreneur.

Six dimensions of
our study

• 01Leadership traits and styles — before, during, and after psychedelic experiences
• 02Motivations for use — personal growth, spiritual exploration, or leadership development
• 03Substance, setting, and context — what's being used, where, and with whom
• 04Perceived impact on team dynamics, organizational relationships, and effectiveness
• 05Social and ecological consciousness — shifts in orientation toward stakeholders
• 06Open-ended reflections — the good, the bad, and the complicated